论文部分内容阅读
目的观察拉米夫定(LAM)与苦参素联合应用与分别单独用药治疗慢性乙型肝炎的疗效。方法将105例慢性乙型肝炎患者随机分为3组:LAM组(35例)单予LAM治疗,苦参素组(35例)予苦参素治疗,联合组(35例)予LAM和苦参素治疗,3组疗程均为12个月。结果经治疗12个月后,LAM组和苦参素组血清HBeAg/抗-HBe转换率和HBV-DNA总转阴率均低于联合组(P均<0.05)。结论拉米夫定与苦参素联合抗病毒治疗,HBeAg/抗-HBe转换率及HBV-DNA转阴率较高,并对于延迟及减少YMDD变异、防止耐药发生而提高疗效起重要作用。
Objective To observe the curative effect of lamivudine (LAM) and oxymatrine combined with monotherapy on chronic hepatitis B. Methods A total of 105 patients with chronic hepatitis B were randomly divided into three groups: LAM group (35 cases) treated with LAM alone, matrine group (35 cases) treated with oxymatrine, combined with LAM (35 cases) Ginseng treatment, three groups of treatment are 12 months. Results After 12 months of treatment, the serum HBeAg / anti-HBe conversion rate and HBV-DNA negative rate in both LAM and oxymatrine groups were lower than those in the combined group (P <0.05). Conclusions Lamivudine and oxymatrine combined with antiviral therapy have higher HBeAg / anti-HBe conversion rate and higher HBV-DNA negative rate, and play an important role in delaying and reducing YMDD mutation and preventing drug resistance and improving the curative effect.